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Introduction: Patients with centrally located lung tumors have been 
reported to have a higher risk of toxicity when treated with stereotac-
tic body radiotherapy (SBRT) compared with patients with periph-
eral tumors. The optimal SBRT fractionation schedule for treatment 
of central tumors is unknown. The primary purpose of this study was 
to assess toxicity in patients with central lesions treated with SBRT at 
our institution, the majority of whom were treated with four fractions.
Methods: Forty-seven patients with 51 central lesions, either pri-
mary lung cancer or lung metastases, were treated with SBRT at the 
Department of Therapeutic Radiology, Yale University School of 
Medicine/Yale Cancer Center from 2007 to 2011. The patients were 
treated with three to five fractions with the majority of patients receiv-
ing 50 Gy in four fractions of 12.5 Gy. Forty of the lesions were located 
within 2 cm of the proximal tracheobronchial tree whereas 11 were 
located within 2 cm of other mediastinal structures. Toxicity data were 
collected and analyzed according to pretreatment and tumor characteris-
tics and dosimetric parameters. Lobar control data were compiled.
Results: With a median follow-up of 11.3 months (range, 4.8–40.8), 
four patients experienced grade 3 dyspnea and one patient developed 
hemoptysis that contributed to respiratory failure and subsequent 
death. Grade 2 toxicity included fatigue (n = 3), dyspnea (n = 3), 
chest-wall pain (n = 1), and cough (n = 1). Patients with grade 3+ 
toxicity had larger maximum tumor diameters compared with those 
patients without grade 3+ toxicity (median diameter 4.3 cm versus 
2.9 cm, p = 0.02). There were no detectable significant differences 
between the two groups with respect to baseline pulmonary function 
tests, distance to tracheobronchial tree, maximum point dose to the 
tracheobronchial tree, maximum dose to 5 cc of the tracheobronchial 
tree, mean lung dose, and volume of lung receiving 5 Gy, 10 Gy, and 
20 Gy. There were two patients who experienced local recurrences. 
The median biological equivalent dose (linear quadratic formula, 
α/β = 10) for patients with local recurrence was 76 Gy compared 
with 112.5 Gy for patients without local recurrence (2-tailed t test, 
p = 0.04). The 2-year actuarial lobar local control for the entire cohort 
was 94%. The 2-year lobar local-control rate for patients receiving 
a biological equivalent dose of 100 Gy or more was 100% and for 
those receiving less than 100 Gy was 80% (log rank, p = 0.02).
Conclusion: SBRT for central lung tumors seems to be safe, although 
treatment of larger tumors does carry an increased risk of high-grade 
toxicity. Efforts to decrease the toxicity risk by decreasing the bio-
logically equivalent dose resulted in increased local failure.
(J Thorac Oncol. 2012;7: 1394–1399)
For patients with medically inoperable early-stage non–small-cell lung cancer (NSCLC), stereotactic body radio-
therapy (SBRT) has emerged as a promising alternative to 
conventional fractionated radiotherapy. The goal of SBRT is to 
deliver tumor-ablative doses of radiation by precisely aiming a 
limited number (typically 1–5) of large radiation fractions at a 
tumor plus a small margin. SBRT has been used increasingly 
to treat medically inoperable early-stage NSCLC and pulmo-
nary oligometastases with excellent results in phase I–II pro-
spective trials.1–5 Radiation Therapy Oncology Group (RTOG) 
0236, the landmark phase II trial for medically inoperable 
early-stage NSCLC, demonstrated a 3-year primary tumor 
control of 97.6% and a 3-year lobar control rate of 90.6% when 
a dose of 54 Gy was delivered in three fractions of 18 Gy.
Despite these encouraging results, there has been con-
cern that the subset of patients with central lung lesions is 
at increased risk for high-grade toxicity. The 4-year results 
of a phase II trial at the University of Indiana showed that 
54 Gy delivered in three fractions of 18 Gy resulted in an 
almost threefold increase in grade 3–5 toxicity for patients 
with central (tumor within 2 cm of the proximal bron-
chial tree) versus peripheral tumors (27.3% versus 10.4%, 
p = 0.088).6 Although this did not reach statistical significance, 
the data raised enough concern that patients with central 
lesions were not enrolled in RTOG 0236. In addition, Song 
et al. 7 reported on nine patients with central tumors treated 
with SBRT (40–60 Gy in 3 or 4 fractions) of whom three 
(33%) developed grade 3–5 pulmonary toxicity.
There is intense interest in identifying an optimal 
dose-fractionation scheme for central lesions, which is not 
only biologically potent enough to eradicate tumors but also 
acceptably safe. The limited available published data suggest 
that SBRT regimens using more than three fractions for central 
lesions might be better tolerated.8–10 This is being prospectively 
studied in RTOG 0813, an ongoing phase I/II trial evaluating 
five-fraction SBRT regimens for early-stage, centrally located 
NSCLC in medically inoperable patients. Although accrual 
for RTOG 0813 is nearing completion, results will not be 
available for some time. The primary purpose of this study 
was to assess toxicity in patients with central lesions treated 
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with SBRT at our institution, the majority of whom were 
treated with four fractions.
PATIENTS AND METHODS
We analyzed 47 consecutive patients with 51 central 
malignant lesions, either primary or recurrent NSCLC, or pul-
monary oligometastases, treated with SBRT at the Department 
of Therapeutic Radiology, Yale University School of Medicine/
Yale Cancer Center from September 2007 to May 2011. Patients 
were offered SBRT for a variety of reasons, including high sur-
gical risk (cardiac disease, poor pretreatment pulmonary func-
tion, inadequate predicted postoperative pulmonary function), 
patient refusal of surgery, and patients with documented meta-
static disease for whom a lobectomy was not considered to be 
justified. A central lesion was defined as a tumor within 2 cm of 
the proximal bronchial tree (RTOG definition) or within 2 cm 
of the heart, great vessels, trachea, or other mediastinal struc-
tures.8 Pretreatment evaluation included a history and physical 
examination by a radiation oncologist as well as an experienced 
thoracic surgeon, baseline bloodwork, and a complete staging 
evaluation including computed tomography (CT) of the chest 
and whole body fluorodeoxyglucose (FDG)-positron emission 
tomography (PET). Patients were discussed prospectively at 
our multidisciplinary thoracic oncology tumor board. Of the 
47 treated patients, 42 had pathologically proven cancer. The 
remaining five patients who did not undergo biopsy were pre-
sumed to have stage I lung cancer. They were discussed at the 
multidisciplinary tumor conference and the consensus opinion 
was that the clinical history and radiographic appearance of the 
lesion were highly suggestive of lung cancer and that the risk 
of the biopsy procedure was too high. Patients with primary 
lung cancer received pulmonary function testing and staging of 
the mediastinum by mediastinoscopy or endobronchial ultra-
sound-guided biopsy.
Simulation/Immobilization
Patients were immobilized in a full-length vacuum 
cushion and underwent a four-dimensional CT scan (2.5-
mm slices) with free breathing. The internal target volume 
was contoured on the average intensity projection using the 
Advantage Workstation (GE Healthcare, Waukesha, WI) and 
was modified to include tumor motion throughout all respira-
tory phases. In rare cases where tumor excursion exceeded 
1 cm, abdominal compression was used.
A uniform 7-mm expansion, accounting for both micro-
scopic spread and intrafraction motion, was added to the inter-
nal target volume to create the planning target volume (PTV). 
The heart, lungs, esophagus, proximal tracheobronchial tree 
(TBT), spinal cord, and brachial plexus were contoured con-
sistent with guidelines provided by RTOG 0236.
Early on in our experience, the majority of patients were 
treated with seven to 13 nonopposing, noncoplanar 6 MV photon 
beams that conformed to the PTV, using a multileaf collimator. 
More recently, we have primarily been using a modified dynamic 
conformal arc technique that has been previously described.11 
Selected patients with tumors particularly close to the brachial 
plexus or immediately abutting a bronchus or other mediasti-
nal structure were treated using intensity-modulated radiation 
therapy. Regardless of the technique used, all plans were normal-
ized such that 95% of the PTV was covered by 100% of the pre-
scription dose and 99% of the PTV was covered by at least 90% 
of the prescription dose. For both forward- and inverse-planned 
cases, the prescription dose was between 70% and 90% of the 
maximum point dose. Dose calculation heterogeneity correc-
tions were performed using the anisotropic analytical algorithm. 
Cone-beam CT image guidance was used for all cases.
Follow-Up/Chart Review
Follow-up consisted of a history and physical examina-
tion and noncontrast chest CT scan every 3 months for 2 years 
and every 6 months thereafter. FDG-PET scans were obtained 
for patients with enlarging lesions on CT or with consolida-
tion that limited evaluation by CT. All hospital records, fol-
low-up notes, and imaging were reviewed and toxicity scored 
according to National Cancer Institute common terminology 
criteria for adverse events, version 4.0. Lobar recurrence was 
defined as a lesion in the treated lobe that was either proven 
by biopsy to be recurrent/persistent disease, was enlarging on 
CT compared with baseline, or had increasing FDG uptake 
on PET. All questionable cases were discussed at tumor board 
and either verified by biopsy or by consensus of the tumor 
board. A variety of patient, tumor, and treatment characteris-
tics were collected, including baseline forced expiratory vol-
ume in the first second, baseline carbon monoxide diffusing 
capacity, corrected for hemoglobin, distance from tumor to 
the proximal TBT, point dose maximum to the TBT (TBT
point
), 
maximum dose received by 5 cc of the TBT (TBT
5cc
), mean 
lung dose (MLD), volume of lung receiving 5 Gy or more 
(V5), volume of lung receiving 10 Gy or more (V10), and 
volume of lung receiving 20 Gy or more (V20).
Statistics
The rate of lobar local control for the entire cohort was 
estimated using the Kaplan–Meier method. The biological equiv-
alent dose (BED, linear quadratic equation, α/β = 10) delivered 
to the two patients with local recurrence was compared with the 
BED delivered to those without recurrence by use of a two-tailed 
t test. Lobar local-control rates were also calculated for patients 
receiving a BED of 100 Gy or more and for those receiving less 
than 100 Gy. These curves were compared using the log rank 
test. The patient, tumor, and treatment characteristics listed above 
were compared between patients who did and did not develop 
grade 3 or higher toxicity by use of a two-tailed t test.
RESULTS
A total of 47 patients with 51 central lesions were 
evaluated. Patient and tumor characteristics are listed in 
Table 1 and treatment characteristics are listed in Table 2. 
Seventy-five percent of the patients received a BED of 100 
Gy or more (range, 60–151.2 Gy) and 57% of the patients 
were treated with 12.5 Gy × 4. Twenty-five percent of the 
patients were treated with a BED of less than 100 Gy in an 
effort to limit normal tissue dose. With a median follow-
up of 11.3 months (range, 4.8–40.8 months), five patients 
experienced grade 3 or higher toxicity (Table 3). One patient 
suffered grade 5 toxicity and it was determined that SBRT 
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likely contributed to his death. This patient was a 75-year-old 
man with metastatic melanoma with a 5.7-cm dominant 
pulmonary metastasis abutting the left mainstem bronchus. 
He developed hemoptysis approximately 10.5 months after 
completing SBRT. He was hospitalized and eventually devel-
oped a collapsed lung and hypoxemia requiring intubation. 
He ultimately died of respiratory failure.
A total of four patients developed grade 3 dyspnea 
(shortness of breath at rest) after completion of SBRT. Three 
of these patients had comorbid chronic obstructive pulmonary 
disease with supplemental oxygen required at baseline. All 
three developed an acute increase in their oxygen requirement 
2 to 4 months after completion of SBRT. They were briefly 
hospitalized and treated with bronchodilators and steroid 
taper with improvement back to their baseline within 1 to 2 
weeks. The fourth patient had metastatic melanoma and devel-
oped cough and shortness of breath 3 months after treatment. 
He was treated for presumed radiation pneumonitis and 
improved with a steroid taper over 4 weeks.
We compared the group of patients with grade 3–5 tox-
icity versus the group without grade 3–5 toxicity and found 
no significant differences in baseline forced expiratory vol-
ume in the first second (percentage predicted), baseline car-
bon monoxide diffusing capacity, corrected for hemoglobin 
(percentage predicted), distance from tumor to the proximal 
TBT, TBT
point
, TBT
5cc
, MLD, V5, V10, or V20. Patients who 
developed grade 3–5 toxicity were found to have significantly 
larger maximum tumor diameters (Table 4). The patient with 
grade 5 toxicity had a TBT
point
 of 54.2 Gy, which was the fifth 
highest point dose of the patients examined. His TBT
5cc
 dose 
was 12.7 Gy, approximately the median.
Two patients had local recurrences a median of 26 
months after treatment. The median BED for the patients with 
local recurrence was 76 Gy (range, 72–80), compared with the 
patients without local failure who had a median BED of 112.5 
Gy (range, 60–151.2; p = 0.04). The 2-year actuarial lobar 
local-control rate for the entire cohort was 94% (Fig. 1). The 
2-year lobar local-control rate for patients receiving a BED of 
100 Gy or more was 100% and for those receiving less than 
100 Gy was 80% (log rank, p = 0.02).
TABLE 1. Patient and Tumor Characteristics
# Lesions treated 51
Age (yrs) median (range) 72 (41–90)
Sex
 Male 22 (47%)
 Female 25 (53%)
ECOG performance status
 0 9 (19%)
 1 28 (60%)
 2 8 (17%)
 3 2 (4%)
Lung primary 30 (59%)
Metastatic lesion 21 (41%)
“Central” definition
 Within 2 cm of proximal tracheobronchial tree 40 (78%)
  Distance to tracheobronchial tree—cm, median (range) 0.65 (0–2)
 Within 2 cm of mediastinum 11 (22%)
  Distance to mediastinum—cm, median (range) 0.5 (0–1.6)
Maximal tumor diameter (cm), median (range) 3.1 (1.1–5.7)
 0–2—# lesions (%) 12 (23.5)
 2–3—# lesions (%) 12 (23.5)
 3–5—# lesions (%) 23 (45)
 5–7—# lesions (%) 4 (8)
Baseline pulmonary function testing
 All patients (47 patients)
 FEV1—liter, median 1.74
 FEV1—% predicted, median 64%
 DsbHb—ml/min/mmHg, median 14.71
 DsbHb—% predicted, median 58%
 Patients medically inoperable due to baseline pulmonary function  
(14 patients)
 FEV1—liter, median 0.99
 FEV1—% predicted, median 38.5%
 DsbHb—ml/min/mmHg, median 10.86
 DsbHb—% predicted, median 41%
FEV1, forced expiratory volume in the first second of expiration; DsbHb, carbon 
monoxide diffusing capacity, corrected for hemoglobin.
TABLE 2. Treatment Characteristics
Treatment technique
 3-D conformal (static beams) 12 (24%)
 Modified dynamic conformal arcs 22 (43%)
 IMRT 17 (33%)
Biological equivalent dose (linear quadratic formula,  
α/β = 10) —Gy, median (range)
112.5 (60–151.2)
 60–79 Gy 3 (5.9%)
 80–99 Gy 10 (19.6%)
 100+ Gy 38 (74.5%)
Lung-dose parameters
 Mean lung dose—Gy, median (range) 4.5 (1.5–11.5)
 V5—%, median (range) 23.9 (8.4–63.1)
 V10—%, median (range) 11.9 (2.6–38.5)
 V20—%, median (range) 5.1 (0.4–18.9)
Dose to TBT
 TBT
point
—Gy, median (range) 39.9 (11.8–60.1)
 TBT
5cc
—Gy, median (range) 14.7 (0–35.4)
3-D, three dimensional; IMRT, intensity-modulated radiation therapy; Gy, gray; V5, 
volume receiving ≥ 5 Gy; V10, volume receiving ≥ 10 Gy; V20, volume receiving ≥ 20 
Gy; TBT, tracheobronchial tree; TBT
point
, maximum point dose to the tracheobronchial 
tree; TBT
5cc
, maximum dose to 5 cc of the tracheobronchial tree.
TABLE 3. Toxicity
Toxicity Grade II III IV V
Fatigue 3
Dyspnea 3 4
Chest-wall pain 1
Hemoptysis 1
Cough 1
Total (% of patients) 8 (17) 4 (9) 0 (0) 1 (2)
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DISCUSSION
The optimal dose-fractionation regimen for central 
lung tumors is not currently known. RTOG 0813, which 
is investigating five-fraction SBRT regimens for centrally 
located NSCLC in medically inoperable patients, will pro-
vide important prospective data in this regard. Several 
groups have reported on their retrospective experience 
treating central lesions with SBRT. Chang et al.8 from MD 
Anderson Cancer Center reported on 27 patients with central 
or superiorly located NSCLC treated with 40 to 50 Gy in 
four fractions. Four patients (28.6%) with recurrent disease 
but none with stage I disease developed grade 2 pneumoni-
tis. A total of three patients (11.1%) developed grade 2–3 
dermatitis and chest-wall pain and one patient with a signifi-
cant volume of brachial plexus receiving 40 Gy developed 
a brachial plexopathy. Bral et al.9 from Belgium reported 
on 17 patients with central lesions treated with 15 Gy × 4 
fractions. They found a correlation between tumor location 
and the development of acute or late grade 3+ pulmonary 
toxicity, with 2-year lung-toxicity–free survival of 84% for 
peripheral lesions versus 60% for central lesions. Haasbeek 
et al.12 from the Netherlands recently reported on 63 patients 
with tumors in a central hilar location or abutting mediasti-
nal structures, who received 7.5 Gy × 8 fractions. Toxicity 
was minimal, with only one patient (2%) experiencing grade 
3 acute toxicity (chest-wall pain) and four patients (6%) 
developing grade 3 late toxicity.
In our series, we did have one patient with toxicity 
from SBRT (bronchopulmonary hemorrhage), which con-
tributed to his death. Of note, a bronchoscopy performed 
during his hospital admission revealed bronchial necrosis in 
the left mainstem bronchus, 2 cm below the carina (Fig. 2). 
The area of necrosis does correspond to the maximum point 
dose of 54.2 Gy, suggesting that the TBT
point
 might be an 
important dose–volume parameter to prevent bronchial 
necrosis and hemoptysis. The four patients in our series with 
TBT
point
 doses higher than 54.2 Gy have shown no signs of 
toxicity, with the longest follow-up among those patients 
being 15 months.
We also identified four patients who developed grade 
3 dyspnea (shortness of breath at rest) 2 to 4 months post-
SBRT. It is possible that all four cases represented radiation 
pneumonitis. Barriger et al.13 have previously reported that 
V20 and MLD were significant dosimetric parameters related 
to the development of radiation pneumonitis after SBRT. Our 
analysis did not reveal a correlation between any of the lung 
or TBT dose parameters and grade 3+ toxicity, although we 
did find that patients with grade 3+ toxicity had larger tumors, 
suggesting an underlying dose–volume correlation to toxicity 
that was not evident in our analysis.
Our data is consistent with previously published reports 
suggesting that a BED of 100 Gy is an important cutoff for 
local control.8,14,15 There have been no local recurrences in 
our series for patients who were treated to a BED of 100 Gy 
or more. It is notable that patients treated to a BED of less 
than 100 Gy in an effort to reduce toxicity had higher local-
failure rates. Our primary reason for analyzing local-control 
outcomes was to compare the relative efficacy of the different 
dose-fractionation regimens. It is important to note that more 
TABLE 4. Comparison of Groups with and without Toxicity
Patients without Grade 3+ Toxicity Patients with Grade 3+ Toxicity p
Maximum tumor diameter—cm, median (range) 2.9 (1.9–5.6) 4.3 (3.1–5.7) 0.02
Baseline FEV1—% predicted, median (range) 64 (22–107) 59 (26–85) 0.45
Baseline DsbHb—ml/min/mmHg, median (range) 59 (23–111) 44 (38–58) 0.26
Distance to TBT—cm, median (range) 0.7 (0–2) 0 (0–1.8) 0.26
TBT
point
—Gy, median (range) 39.8 (15.2–60.0) 40.0 (11.8–54.2) 0.68
TBT
5cc
—Gy, median (range) 15.4 (0–35.4) 11.0 (3.1–14.3) 0.25
MLD—Gy, median (range) 4.5 (1.51–11.5) 5.9 (3.0–7.8) 0.46
V5—%, median (range) 23.7 (8.4–43.9) 26.9 (17.8–49) 0.25
V10—%, median (range) 11.9 (2.6–38.5) 16.5 (6.6–35.6) 0.23
V20—%, median (range) 5.1 (0.4–18.9) 3.3 (2.4–13.2) 0.95
FEV1, forced expiratory volume in the first second of expiration; DsbHb, carbon monoxide diffusing capacity, corrected for hemoglobin; TBT, tracheobronchial tree; TBT
point
, 
maximum point dose to the TBT; TBT
5cc
, maximum dose to 5 cc of the TBT; MLD, mean lung dose; V5, volume of lung receiving ≥ 5 Gy; V10, volume of lung receiving≥ 10 Gy; 
V20, volume of lung receiving ≥ 20 Gy.
FIGURE 1. Local control. Actuarial lobar local control esti-
mated for the entire cohort using the Kaplan–Meier method.
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than half the patients in this cohort had either metastatic or 
recurrent disease and therefore had limited survival and were 
censored from the local-control analysis at the time of their 
death. It is likely that the local control will be lower with longer 
follow-up.
Our study is subject to all the usual limitations and 
biases present in retrospective studies and should, therefore, 
be interpreted as hypothesis generating. Although we thor-
oughly reviewed all available records for toxicity informa-
tion, it is possible that toxicity events, especially grade 1 or 
2 events, were missed. For this reason, we did not include 
grade 1 events in our report. In addition, because the number 
of grade 3 or higher events was low (n = 5), and our patient 
population relatively small and heterogeneous, our ability 
to correlate high-grade toxicity with clinical factors is lim-
ited. Last, because late toxicity—such as bronchial stenosis, 
hemoptysis, or decline in pulmonary function—can manifest 
beyond the median follow-up time for our cohort, toxicity 
rates should be interpreted with caution and longer follow-up 
will be necessary.
Overall, the toxicity with this regimen seems to be accept-
able, although caution needs to be exercised when considering 
SBRT for larger central tumors. Given the reasonable toxicity 
and increased risk of local failure with attenuated doses in our 
series, we will be more inclined to treat central lesions to full 
dosages (BED ≥100 Gy) in the future. Further work is needed 
to define optimal dose–volume constraints. Long-term follow-
up of these patients is obviously needed to confirm the results.
CONCLUSIONS
SBRT for central lung tumors seems to be safe, although 
treatment of larger tumors does carry an increased risk of 
high-grade toxicity. Efforts to decrease the toxicity risk 
by decreasing the biologically equivalent dose resulted in 
increased local failure.
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